Eli Lilly reported new Phase 3 top-line results for retatrutide in obesity, with all tested doses meeting primary and key secondary endpoints and driving average weight loss in the range of 19% to 28.3% over 80 weeks. The program also reported improvements in cardiovascular risk factors, while side effects including nausea, diarrhea, constipation, and vomiting emerged in the safety profile. Lilly said the next round of data details is scheduled for presentation next month at the American Diabetes Association Scientific Sessions, as the company prepares for future regulatory steps. In the broader development context, retatrutide is already tied to earlier Phase 3 wins in type 2 diabetes and in an obesity/osteoarthritis knee pain study. Separately, another report on the same dataset noted retatrutide’s weekly injection targets three receptors—GLP-1, glucagon, and GIP—positioning it as “triple-G” relative to the two-receptor approach of tirzepatide and the single-receptor GLP-1 targeting of semaglutide-based therapies. Together, the obesity results intensify competitive pressure across the weight-loss market ahead of FDA review timing and payer decisions that increasingly hinge on magnitude of loss and tolerability.